InBrain Pharma will present long-term follow-up data from its Phase I/II DIVE-I study at the International Conference of Parkinson’s Disease and Movement Disorders (MDS) 2025, to be held October 5–9 in Honolulu, Hawaii, the company said. The oral presentation is scheduled for October 8 at 12:00 pm (HAST), delivered by Prof. David Devos, with an accompanying e-poster session.
According to the company, the new data confirm a favorable safety profile for continuous intracerebroventricular infusion of A-dopamine in advanced Parkinson’s patients who are refractory to L-dopa. InBrain claims the results also demonstrate sustained motor control benefits over the long term.
The DIVE-I trial is expected to reach full completion on September 30, 2025. The presentation will be made under Abstract LBA 16 in Session OPP12, Clinical Trials, Room 312.
InBrain Pharma describes itself as a pioneer in neurology therapies, developing brain-infused A-dopamine. The company holds an exclusive worldwide license from SATT Nord and says it is preparing for Phase III development following a positive opinion from the European Medicines Agency (EMA). It recently secured €1.8 million in funding under France’s “First Factory” initiative and obtained support from France Parkinson.
